AI assistant
Spyre Therapeutics, Inc. — Director's Dealing 2016
Apr 15, 2016
32226_dirs_2016-04-14_e92e3a7d-3a14-4a5e-8100-37f8c5461c82.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2016-04-06
Reporting Person: LILLY ELI & CO (10% Owner)
Reporting Person: Lilly Ventures Fund I LLC (10% Owner)
Reporting Person: Shanafelt Armen (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 57619 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Preferred Stock | $0.0 | Common Stock (890476.0) | Indirect | ||
| Series B Preferred Stock | $0.0 | Common Stock (1120448.0) | Indirect |
Footnotes
F1: These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.
F2: Each share of Series A Preferred Stock and Series B Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.